Dimephosphon^® (Solution, Concentrate) Instructions for Use

ATC Code

V03AX (Other therapeutic agents)

Clinical-Pharmacological Group

Acid-base balance correction preparation

Pharmacotherapeutic Group

Antiacidotic agent

Pharmacological Action

An antiacidemic agent, it normalizes the acid-base state in acidosis of various etiologies by activating metabolic mechanisms of its regulation (especially renal and pulmonary), enhancing intraorgan blood flow and tissue metabolism.

It has cerebrovasodilatory, nootropic, antidepressant, anti-edematous, anti-ischemic, stress-protective, mnemetropic and anti-amnesic, anti-allergic, membrane-stabilizing, immunomodulatory, antihypoxic, antimutagenic and radioprotective effects, suppresses platelet aggregation, and stimulates tissue regeneration.

It dose-dependently reduces the intensity of lipid peroxidation, inhibits spontaneous and ADP-induced aggregation, increases the antioxidant activity of platelets, and reduces the content of lipid peroxidation products in them.

It improves cerebral circulation, normalizes the tone of cerebral vessels and cerebral blood filling, and improves venous outflow. Neurotropic activity and cerebroprotective properties are due to the impact on the mechanisms of neurometabolic protection of the brain (normalizes carbohydrate and energy metabolism, prevents activation of lipid peroxidation, increases the activity of antioxidant enzymes in brain tissue).

In traumatic brain injury, it has a beneficial effect on its metabolism and electrical activity; eliminates vasomotor cephalalgia; reduces oxygen consumption by brain tissues, cardiac and respiratory failure of central origin, and promotes regression of focal hemispheric and brainstem symptoms.

It eliminates allergic inflammation, in particular, during the development of leukotriene-dependent sulfite intolerance reaction, reduces the severity of manifestations of atopic bronchial asthma and atopic dermatitis.

In combination with vitamins, pancreatic enzymes, and cholestyramine in children with hereditary entero-oxaluric syndrome, it slows the progression of the disease and increases life expectancy.

With topical application, it has an antiseptic effect and increases the protective functions of the skin and mucous membranes.

Pharmacokinetics

After a single oral dose, it is absorbed sufficiently completely. The time to reach C_max is 2-2.5 hours. It easily passes histohematic barriers and is distributed to various organs and tissues. The highest concentrations are created in the spleen, brain, and erythrocytes.

Indications

Acidosis in pneumonia, chronic lung diseases, acute respiratory viral infections, diabetes mellitus, and in the postoperative period; bronchospastic variant of bronchial obstruction (chronic bronchitis, bronchial asthma, including atopic bronchial asthma in children); subcompensated hypertension in the “lesser” circulation; pollinosis in children; transient ischemic attacks, ischemic and hemorrhagic stroke (initial manifestations, consequences of a previous stroke); dyscirculatory encephalopathy (including against the background of arterial hypertension); myelopathy, radiculopathy; neurosurgical operative trauma of the brain and spinal cord; traumatic brain injury (concussion and contusion of the brain); Ménière’s syndrome and disease, autonomic lability; atopic dermatitis; infectious-inflammatory-allergic diseases of the skin and mucous membranes: acne, erysipelas, purulent-inflammatory complications at the exit sites of Ilizarov apparatus wires; diseases of ENT organs and dental diseases; mucositis during radiation therapy for malignant neoplasms; infected wounds, trophic ulcers; rickets-like diseases in children; hereditary entero-oxaluric syndrome.

ICD codes

Dosage Regimen

Solution, Concentrate

Orally (it is recommended for children to wash it down with milk, fruit juice, sweet tea; it has a bitter taste), 30-50 mg/kg 1-4 times/day: for cerebrovascular disorders and Ménière’s syndrome – for 1-4 weeks, for planned neurosurgical operations – 5 days before and 10-14 days after surgery, for traumatic brain injury – 3-8 weeks; for autonomic dysfunction, respiratory diseases, acidosis, atopic bronchial asthma (in children) – 2-4 weeks; for prevention of pollinosis exacerbation – 3 weeks before the expected seasonal deterioration and throughout the flowering of the allergen plant.

Topically. For infectious-inflammatory-allergic diseases of the skin and mucous membranes – in the form of dressings, turundas and lotions with the solution daily for 3-14 days; for prevention of radiation mucositis – gauze napkins moistened with the solution are placed in the projection of the radiation beams 20 minutes before dose exposure.

Intravenously bolus – the contents of 1-2 ampoules are diluted in 10-20 ml of sterile water for injections or 0.9% sodium chloride solution, drip – in 200-400 ml of 0.9% sodium chloride solution. Administered 1-4 times/day for 7-10 days.

Adverse Reactions

Nausea, vomiting, heartburn, diarrhea (when taken orally), drowsiness (at the beginning of treatment).

Contraindications

Hypersensitivity; chronic renal failure stage II-III; epilepsy.

Use in Renal Impairment

Contraindicated in chronic renal failure stage II-III.

Special Precautions

If drowsiness occurs, refrain from driving vehicles and engaging in activities requiring increased attention and speed of reactions.

Drug Interactions

Enhances the antiplatelet effect of acetylsalicylic acid.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.